Viridian Therapeutics, Inc./DE (VRDN) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -405.20M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 151.65M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-405.20M | (m) | (m) | (m) | $151.65M | (m) |
| 2026-03-31 | $-385.70M | (m) | (m) | (m) | $116.89M | (m) |
| 2025-12-31 | $-363.39M | (m) | (m) | (m) | $95.31M | (m) |
| 2025-09-30 | $-328.12M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $-371.58M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $-337.00M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $-299.04M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $-283.04M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $-250.78M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $-237.87M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-254.45M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $-232.04M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-210.60M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-180.89M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-134.30M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $-114.32M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-98.67M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-87.10M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-79.73M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $-141.25M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $-132.52M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $-120.90M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-110.38M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $-29.85M | (m) | (m) | $21.47M | (m) | (m) |
| 2020-06-30 | $-35.67M | (m) | (m) | $27.38M | (m) | (m) |
| 2020-03-31 | $-38.24M | (m) | (m) | $32.15M | (m) | (m) |
| 2019-12-31 | $-41.98M | (m) | (m) | $34.79M | (m) | (m) |
| 2019-09-30 | $-42.36M | (m) | (m) | $34.61M | (m) | (m) |
| 2019-06-30 | $-40.28M | (m) | (m) | $32.98M | (m) | (m) |
| 2019-03-31 | $-40.20M | (m) | (m) | $32.76M | (m) | (m) |
| 2018-12-31 | $-33.08M | (m) | (m) | $30.42M | (m) | (m) |
| 2018-09-30 | $-28.98M | (m) | (m) | $27.18M | (m) | (m) |
| 2018-06-30 | $-25.72M | (m) | (m) | $24.80M | (m) | (m) |
| 2018-03-31 | $-24.21M | $8.32M | (m) | $21.92M | (m) | -290.83% |
| 2017-12-31 | $-26.53M | $4.00M | (m) | $19.62M | (m) | -662.80% |
| 2017-09-30 | $-21.61M | $3.18M | (m) | $5.73M | (m) | -679.65% |
| 2017-06-30 | $-19.81M | (m) | (m) | $3.67M | (m) | (m) |
| 2017-03-31 | $-15.91M | (m) | (m) | $1.54M | (m) | (m) |
| 2016-12-31 | $-12.51M | $3.34M | (m) | $888.00K | (m) | -374.83% |
| 2016-09-30 | $-9.99M | (m) | (m) | $1.32M | (m) | (m) |
| 2016-06-30 | $-11.30M | (m) | (m) | $1.35M | (m) | (m) |
| 2016-03-31 | $-11.31M | (m) | (m) | $1.21M | (m) | (m) |
| 2015-12-31 | $-11.19M | (m) | (m) | $1.00M | (m) | (m) |
| 2015-09-30 | $-10.49M | (m) | (m) | $572.00K | (m) | (m) |
| 2015-06-30 | $-8.99M | (m) | (m) | $424.00K | (m) | (m) |
| 2015-03-31 | $-9.31M | (m) | (m) | $358.00K | (m) | (m) |
| 2014-12-31 | $-6.87M | (m) | (m) | $293.00K | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-197.00K | (m) | (m) | $225.00K | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |